Bavarian Nordic A/s logo

Bavarian Nordic A/s(OTC) BVNKF

Market Cap$2.74BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+4%
5 Year-23%
1 Year+0%
1 Month+11%
$36.06
+7.13%
+2.40Today
Bavarian Nordic A/s last closing stock price
MetricPriceDate
Last closeUSD 36.062026-10-08
Bavarian Nordic A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+7.15%USD 33.662026-09-29
1 month+10.72%USD 32.572026-08-31
3 month+30.22%USD 27.692026-07-09
Year to date+22.24%USD 29.502025-12-31
1 year+0.15%USD 36.012025-10-07
3 year+67.1%USD 21.582023-10-05
5 year-23.28%USD 47.002021-10-05
Since inception+4.07%USD 34.652003-11-14

Bavarian Nordic A/s Financials at a Glance

Market Cap

$2.74BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

DKK 6.29B

Net Income (TTM)

DKK 1.54B

EPS (TTM)

$3.12

P/E Ratio

11.54

Dividend

$0.00

Beta (Volatility)

0.34 (Low)

Price

$36.06

Volume

208

Open

$33.99

Previous Close

$36.06

Daily Range

$33.99 - $36.06

52-Week Range

$27.69 - $37.22

Estimated Earnings Date

Nov 13, 2026

BVNKF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bavarian Nordic A/s

Bavarian Nordic A/S is a biotechnology company focused on developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. Headquartered in Hellerup, Denmark, the company specializes in therapeutic vaccines targeting various cancers, including breast, lung, ovarian, and prostate cancer.

Products and Services
  • Therapeutic vaccines for cancer treatment
  • Vaccines for infectious diseases
  • Research and development in immunotherapy
Growth Outlook
  • Recent quarterly revenue reached DKK 2.02 billion, indicating strong demand
  • Net income for Q2 2026 was DKK 729 million, showcasing profitability
  • Cash and short-term investments totaled DKK 2.35 billion, providing financial stability
Financial Highlights
  • Trailing twelve months (TTM) revenue of DKK 6.4 billion reflects robust growth
  • Net profit margin of 24.5% demonstrates effective cost management
  • Current ratio of 6.53 indicates strong liquidity position
Bavarian Nordic A/S is positioned in a growing sector with a focus on innovative therapies. The company's recent financial performance highlights its ability to generate significant revenue and maintain profitability. With a strong liquidity position, Bavarian Nordic is well-equipped to invest in future growth opportunities and expand its product offerings. The focus on cancer immunotherapy aligns with increasing global demand for effective cancer treatments, making Bavarian Nordic a noteworthy player in the biotechnology industry.
AI Generated • Sep 18, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,906

CEO

Paul Chaplin, PhD

Website

www.bavarian-nordic.com

Headquarters

Hellerup, CR 2900, DK

BVNKF Financials

Key Financial Metrics (TTM)

Gross Margin

49.53%

Operating Margin

29.77%

Net Income Margin

24.50%

Return on Equity

11.88%

Return on Capital

7.08%

Return on Assets

10.48%

Earnings Yield

8.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.74BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

75.99M

Volume

208

Avg. Volume

75.446

Financials (TTM)

Gross Profit

DKK 3.11B

Operating Income

DKK 1.87B

EBITDA

DKK 2.62B

Operating Cash Flow

DKK 1.43B

Capital Expenditure

-DKK 199.62M

Free Cash Flow

DKK 1.24B

Cash & ST Invst.

DKK 2.35B

Total Debt

DKK 130.87M

Bavarian Nordic A/s Performance Analysis

Bavarian Nordic A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31DKK 445,115,54548.1%
20232023-12-31DKK 1,023,994,200130.1%
20242024-12-31DKK 828,183,526-19.1%
20252025-12-31DKK 933,164,96812.7%
Bavarian Nordic A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-308.7%
Q42025-12-31-21.4%
Q12026-03-31-24.8%
Q22026-06-3090.9%
Bavarian Nordic A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31DKK -0.70-40.5%
20232023-12-31DKK 2.79N/A
20242024-12-31DKK 1.83-34.3%
20252025-12-31DKK 2.6745.3%
Bavarian Nordic A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30204.4%
Q42025-12-31-127.9%
Q12026-03-31105.8%
Q22026-06-304268.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

DKK 2.02B

+22.5%

Gross Profit

DKK 1.22B

+33.9%

Gross Margin

60.45%

N/A

Market Cap

$2.74BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.53M

N/A

Employees

1,795

N/A

Net Income

DKK 729.04M

+101.1%

EBITDA

DKK 917.58M

+68.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

DKK 2.35B

+41.3%

Total Debt

DKK 130.87M

-3.8%

Accounts Receivable

DKK 1.56B

+72.3%

Inventory

DKK 2.67B

+1.0%

Long Term Debt

DKK 85.10M

-9.4%

Short Term Debt

DKK 45.77M

+8.6%

Return on Assets

10.48%

N/A

Return on Invested Capital

13.69%

N/A

Free Cash Flow

DKK 328.42M

-29.7%

Operating Cash Flow

DKK 349.82M

-72.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,803.85-0.00%
^DJIDJI
$51,687.96-0.00%
^IXICNASDAQ
$27,201.84-0.00%
BTCBitcoin
$83,069.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
BACBank of America
$50.04-7.27%
CRWVCoreWeave
$67.03-13.85%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$40.28+7.64%
CIFRCipher Digital
$10.55-7.01%

Questions About BVNKF

What is the current price of Bavarian Nordic A/s?

Bavarian Nordic A/s is trading at $36.06 per share.

What is the 52-week range for Bavarian Nordic A/s?

Over the past 52 weeks, Bavarian Nordic A/s has traded between $27.69 and $37.22.

How much debt does Bavarian Nordic A/s have?

As of the most recent reporting period, Bavarian Nordic A/s reported total debt of DKK 20.09M.

How much cash does Bavarian Nordic A/s have on hand?

Bavarian Nordic A/s reported DKK 118.80M in cash and cash equivalents in its most recent financial results.

What is Bavarian Nordic A/s’s dividend yield?

Bavarian Nordic A/s does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services